Sinegin 3
Sinegin 3 Basic information
- Product Name:
- Sinegin 3
- Synonyms:
-
- Onjisaponin B, >=98%
- Onjisaponin B
- Senegin III
- Sinegin 3
- Olean-12-ene-23,28-dioic acid, 3-(β-D-glucopyranosyloxy)-2,27-dihydroxy-, 28-[O-6-deoxy-α-L-mannopyranosyl-(1→3)-O-[O-β-D-galactopyranosyl-(1→4)-O-β-D-xylopyranosyl-(1→4)-6-deoxy-α-L-mannopyranosyl-(1→2)]-6-deoxy-4-O-[(2E)-3-(4-methoxyphenyl)-1-oxo-2-propen-1-yl]-β-D-galactopyranosyl] ester, (2β,3β,...
- Onjisaponin B, 10 mM in DMSO
- CAS:
- 35906-36-6
- MF:
- C75H112O35
- MW:
- 1573.67
- Product Categories:
-
- Triterpenoids
- Mol File:
- 35906-36-6.mol
Sinegin 3 Chemical Properties
- Density
- 1.54±0.1 g/cm3 (20 ºC 760 Torr)
- solubility
- Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
- form
- Powder
- pka
- 4.14±0.70(Predicted)
- color
- White to off-white
Sinegin 3 Usage And Synthesis
Chemical Properties
White crystalline powder, soluble in organic solvents such as methanol, ethanol, and DMSO. It is derived from Polygala tenuifolia Willd.
Uses
Onjisaponin B is an orally active natural product derived from Polygala tenuifolia. Onjisaponin B inhibits NF-κB p65. Onjisaponin B enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin. Onjisaponin B reduces β-amyloid (Aβ) production. Onjisaponin B reduces radiation-induced cell apoptosis. Onjisaponin B has anti-oxidant and anti-inflammatory activities. Onjisaponin B can be used for neurological disease and radiation injury study, and its metabolite tenuifolin (TF) can enter the brain through the BBB[1][2][3][4].
Definition
ChEBI: Senegin III is a triterpenoid saponin isolated from Polygala senega var latifolia and has been shown to exhibit hypoglycemic activity. It has a role as a hypoglycemic agent and a plant metabolite. It is a cinnamate ester, a hydroxy monocarboxylic acid, a pentacyclic triterpenoid and a triterpenoid saponin. It is functionally related to a 4-methoxycinnamic acid. It derives from a hydride of an oleanane.
in vivo
Onjisaponin B (40 mg/kg; i.g.; once) cannot pass through the blood-brain barrier (BBB), but its metabolite tenuifolin (TF) can enter the brain through the BBB in mice[2].
Onjisaponin B (20-40 mg/kg; i.g.; daily for 12 days) ameliorates dopaminergic (DA) neurodegeneration in a MPTP (HY-15608)-induced mouse model of Parkinson’s disease (PD) through anti-oxidant and anti-inflammatory activities mediated via the RhoA/ROCK2 signaling pathway[2].
Onjisaponin B (10 mg/kg; p.o.; daily from 4 to 7 months of age) reduces β-amyloid production and improve cognitive impairments in transgenic mice[3].
Onjisaponin B (2.5 mg/kg; p.o.; 4 days prior to irradiation) significantly reduces pathological changes and apoptosis and the nuclear translocation of p65 in the lung tissue of p65+/- mice following radiation[4].
| Animal Model: | C57BL/6J-Relaem1Smoc mice (p65+/- mice)[4] |
| Dosage: | 2.5 mg/kg |
| Administration: | Oral gavage (p.o.); 4 days prior to irradiation |
| Result: | Inhibited p65 and cas3 activation caused by p65, and significantly reduced pathological changes and apoptosis (caused by down-regulation of p65) and the nuclear translocation of p65 in the lung tissue of p65+/- mice following radiation, but not in the thymus. |
| Animal Model: | C57BL/6J mice (male, 12 weeks old)[2] |
| Dosage: | 20, 40 mg/kg |
| Administration: | Intragastric gavage (i.g.); daily for 12 days |
| Result: | Had a neuroprotective effect on MPTP (HY-15608) induced Parkinson’s disease (PD) model mice. Recovered MPTP-induced motor impairment. Reduced the number of ionized calcium-binding adapter molecule 1 (IBA-1)-positive cells, suppressed microglial activation induced by MPTP. Inhibited the secretion of IL-1β, TNF-α, and IL-6. Decreased MDA levels but increased SOD levels, exerted antioxidant abilities in PD model mice. |
| Animal Model: | APPswe/PS1ΔE9 (APP/PS1) double-transgenic mice[3] |
| Dosage: | 10 mg/kg (200 μL (1 mg/mL) per 20 g body weight) |
| Administration: | Oral gavage (p.o.); daily from 4 to 7 months of age |
| Result: | No obvious toxic effects in mice. Did not alter mouse locomotor activity. Ameliorated cognitive impairments in amyloid precursor protein (APP)/ presenilin 1 (PS1) mice. Showed significantly lower numbers of 6E10-positive Aβ plaque and reduced plaque area. |
References
[1] Wu AG, et al. Onjisaponin B derived from Radix Polygalae enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin in PC-12 cells. Int J Mol Sci. 2013 Nov 15;14(11):22618-41. DOI:10.3390/ijms141122618
[2] Peng F, et al. The onjisaponin B metabolite tenuifolin ameliorates dopaminergic neurodegeneration in a mouse model of Parkinson's disease. Neuroreport. 2020 Apr 8;31(6):456-465. DOI:10.1097/WNR.0000000000001428
[3] Li X, et al. Traditional Chinese Nootropic Medicine Radix Polygalae and Its Active Constituent Onjisaponin B Reduce β-Amyloid Production and Improve Cognitive Impairments. PLoS One. 2016 Mar 8;11(3):e0151147. DOI:10.1371/journal.pone.0151147
[4] Wang TY, et al. Targeting p65 to inhibit Cas3 transcription by Onjisaponin B for radiation damage therapy in p65+/- mice. Phytomedicine. 2022 Sep;104:154317. DOI:10.1016/j.phymed.2022.154317
Sinegin 3Supplier
- Tel
- 0411-62910999 13889544652
- sales@meilune.com
- Tel
- 021-61312847 13636370518
- shyysw007@163.com
- Tel
- +86-028-82633397 18982077548
- cwb1@biopurify.cn
- Tel
- 021-38218169 13341702378
- winherb@126.com
- Tel
- 021-51320588
- tauto@tautobiotech.com
Sinegin 3(35906-36-6)Related Product Information
- (3-sinapoyl)fructofuranosyl-(6-sinapoyl)glucopyranoside
- sibiricaxanthone B
- polygalic acid
- SENEGENIN
- Polygalacin D
- Tenuifoliside C
- polygalaxanthone III
- Tenuifoliside B
- Tenuifoliose A
- Arillanin A
- sibiricaxanthone A
- Onjisaponin A
- Tenuifoliside A
- senegin II
- Onjisaponin O
- Tenuifoliose J
- Polygalasaponin F
- 3-O-Feruloylsucrose